Le Lézard
Classified in: Health, Science and technology
Subject: FVT

Satellite Symposium Addresses The Role of Advanced Multiplex Molecular Testing in Diagnostic Stewardship


Program developed by Medavera, Inc. will take place during IDWeek 2024

LOS ANGELES, Oct. 5, 2024 /PRNewswire/ -- With infectious diseases ranking as the third leading cause of death globally and the growing health threat of antimicrobial resistance, multiplex molecular assays are emerging as a powerful new diagnostics tool. During a live satellite symposium held during IDWeek 2024, three global infectious disease experts will be addressing emerging challenges and highlighting how these assays can transform diagnostic stewardship. The program was planned and developed by Medavera, Inc., a leading provider of medical education.

IDWeek 2024 is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

This free symposium Navigating Advanced Testing Options to Improve Diagnostic Stewardship will be available to IDWeek 2024 attendees. It will be held on Wednesday, October 16th at the JW Marriott Los Angeles, Platinum Ballroom A-C, from 11:00 a.m. to 1:00 p.m. (PST). A buffet lunch will be provided.

The expert presenters include:

There will be an opportunity to engage with the panelists during a live Q & A session following the presentations. This program is accredited for up to 1.5 continuing education hours/credits for physicians, nurses, laboratory professionals, and pharmacists.

Pre-registration is available at www.StewardshipCME.com

This activity was planned and developed by Medavera, Inc. Educational support was provided by QuidelOrtho. This program is not an official event, nor sponsored, endorsed, or accredited by IDWeek.

SOURCE Medavera, Inc.


These press releases may also interest you

at 00:50
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds of Late-Breaking Clinical Trials presented at the...

at 00:45
Revenues -5% yoy organic TDA, -3% yoy organic, a solid result given market conditions, high comparison base; volumes stabilisingBy GBU, Adecco -5%, with good results across Asia, Iberia, EEMENA, LatAm outweighed by challenging markets, particularly...

at 00:07
The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and access innovative new medicines. The pilot will test a new...

4 nov 2024
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral...

4 nov 2024
Kenvue Canada Inc., a division of Kenvue Inc. ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®, announced the completion of its newly...

4 nov 2024
Hugel Inc., a leading global medical aesthetics company, said on Tuesday that WELLAGE, its clinical derma cosmetics brand for skin wellness, joined the festival K-beauty Boost in NYC 2024 at the Korean Cultural Center New...



News published on and distributed by: